Overview of Emerging Neurotechnologies Entering the Marketplace

February 15, 2007 Overview of Emerging Neurotechnologies Entering the Marketplace In his presentation to the National Task Force on Consumer Access to Emerging Neurotechnologies, John OReardon, M.D., Assistant Professor of Psychiatry, elaborated on current and emerging technologies for people with treatment resistant depression. Dr. John OReardon was able to share his expertise on emerging neuromodulation therapies in psychiatry with the National Task Force on Consumer Access to Emerging Neurotechnologies. Dr. OReardon provided details about three emerging modulation devices: Vagus Nerve Stimulation (VNS) currently approved by the Food and Drug Administration (FDA) for treatment resistant depression (2005) and adjunctive therapy . . .